Showing results (81-90 of 146) with videos related to

Sort By:
Pageof 15
Oncotargets and Therapy|August 28, 2020
Atypical Mature T-Cell Neoplasms: The Relevance of the Role of Flow CytometryTeodora Statuto, Fiorella D'Auria, Luigi Del Vecchio, et al.
Frontiers in Oncology|November 1, 2021
Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell LymphomaSabrina Manni, Anna Fregnani, Laura Quotti Tubi, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 5, 2015
Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life EvaluationRenato Zambello, Laura Bonaldi, Tamara Berno, et al.
Cancers|September 9, 2022
CK1α/RUNX2 Axis in the Bone Marrow Microenvironment: A Novel Therapeutic Target in Multiple MyelomaAnna Fregnani, Lara Saggin, Ketty Gianesin, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 3, 2015
Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic LeukemiaAndrea Visentin, Monica Facco, Federica Frezzato, et al.
Plos One|October 3, 2013
Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cellsSabrina Manni, Alessandra Brancalion, Elisa Mandato, et al.
Annals of Hematology|December 13, 2018
Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRIRenato Zambello, Filippo Crimì, Albana Lico, et al.
Oncotarget|August 28, 2016
A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemiaIlaria Laurenzana, Antonella Caivano, Stefania Trino, et al.
Cancer Reports (Hoboken, N.J.)|April 25, 2024
When Waldenström macroglobulinemia hits the kidney: Description of a case series and management of a "rare in rare" scenarioNicolò Danesin, Greta Scapinello, Dorella Del Prete, et al.
Oncotarget|January 19, 2017
Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathwaysSabrina Manni, Marilena Carrino, Martina Manzoni, et al.
Pageof 15